IP Library Granted Patent US 11,576,905
Granted Patent B2
US 11,576,905 · App. 16/638,621 · Granted Feb 14, 2023

Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage

Inventors: José Agustín Rogelio Magaña Castro (Mexico City, MX); Juan Socorro Armendáriz Borunda (Mexico City, MX)
Assignee: Excalibur Pharmaceuticals, Inc.
A61K31/4418A61K31/351A61P17/02A61K9/0014A61K9/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,576,905
App. No.
16/638,621
Granted
Feb 14, 2023
Kind
B2
Abstract

The invention provides topical pharmaceutical gel compositions for the treatment of chronic skin damage, specifically for damage caused by neuropathic ulcers and preferably for the treatment of diabetic foot, and in the treatment of vascular ulcers wherein said compositions comprise a combination of Modified Diallyl Disulfide Oxide (M-DDO) (as an antiseptic/antibiotic agent) and 5-methyl-1-phenyl-2(1H)-pyridone. Furthermore, the invention describes methods of treatment, applications and/or pharmaceutical uses in the preparation of medicaments for eliminating, reducing or preventing chronic skin lesions and the damages caused by neuropathic ulcers and particularly in the treatment of diabetic foot and in the treatment of vascular ulcers.

Claims (45)

1. A method of treating chronic skin damage in a subject in need thereof, the method comprising administering to skin of the subject a topical pharmaceutical gel composition comprising modified-diallyl disulfide oxide, 5-methyl-1-phenyl-2(1H)-pyridone, and one or more pharmaceutically acceptable excipients; wherein the chronic skin damage is caused by vascular ulcers, decubitus ulcers, arterial ulcers, or venous ulcers.

2. The method of claim 1 , wherein the composition comprises from 0.01 to 0.1% weight/weight of modified-diallyl disulfide oxide, from 5 to 10% weight/weight of 5-methyl-1-phenyl-2(1H)-pyridone, and from 89% to 95% weight/weight of one or more pharmaceutically acceptable excipients.

3. The method of claim 1 , wherein the one or more pharmaceutically acceptable excipients are gel-forming agents, neutralizing agents, wetting agents, flavoring agents, stains, and aqueous solvent.

4. The method of claim 3 , wherein the gel-forming agent is selected from the group consisting of Carbomer, Carbopol 940, Carbopol 940P, Neopol 40, glycerin polyacrylates, crosslinked alkyl acrylates, polyacrylamides, acrylic acid polymers, methylcellulose, polyethylene glycols of high molecular weight, and sodium carboxymethyl cellulose.

5. The method of claim 3 , wherein the neutralizing agent is selected from the group consisting of amines, sodium hydroxide, potassium hydroxide, triethanolamine, aminomethylpropanol, and 2,2′,2″-nitrilotrietanol.

6. The method of claim 3 , wherein the wetting agent is selected from the group consisting of polyols, glycerin, sorbitol, propylene glycol, polyethylene glycol, and 1,2-propanediol.

7. The method of claim 3 , wherein the flavoring agent and the stain are selected from the group comprising natural essences, essential oils, extracts, balsams, compounds isolated from natural essences, compounds isolated from aromatic sapid chemical compound extracts, or compounds isolated from artificial sapid chemical compound extracts.

8. The method of claim 1 , wherein the composition comprises an aqueous solvent selected from the group comprising water and mixtures of water-soluble alcohol and water.

9. The method of claim 3 , wherein the gel-forming agent is present in an amount equivalent to 0.5 to 1.5% weight/weight of the composition.

10. The method of claim 3 , wherein the wetting agent is present in an amount equivalent to 38 to 45% weight/weight of the composition.

11. The method of claim 3 , wherein the neutralizing agent is present in an amount equivalent to 0.5 to 1.5% weight/weight of the composition.

12. The method of claim 3 , wherein the flavoring agents and the dye stains are each present in an amount not greater than 0.01% weight/weight of the composition.

13. The method of claim 1 , wherein the chronic skin damage is caused by vascular ulcers.

14. The method of claim 1 , wherein the chronic skin damage is caused by decubitus ulcers.

15. The method of claim 1 , wherein the chronic skin damage is caused by arterial ulcers.

16. The method of claim 1 , wherein the chronic skin damage is caused by venous ulcers.

17. The method of claim 1 , wherein the composition comprises:

(i) 8% 5-methyl-1-phenyl-2(1H)-pyridone by weight;

(ii) 0.016% modified-diallyl disulfide oxide by weight;

(iii) 1% Carbomer 940 by weight;

(iv) 40% propylene glycol by weight;

(v) 1% triethanolamine by weight; and

(vi) 49.984% water by weight.

18. The method of claim 1 , wherein the composition comprises:

(i) 8% 5-methyl-1-phenyl-2(1H)-pyridone by weight;

(ii) 0.016% modified-diallyl disulfide oxide by weight;

(iii) 1% Carbomer 940 by weight;

(iv) 50% propylene glycol by weight;

(v) 1% triethanolamine by weight;

(vi) 13% macrogol-glycerol hydroxystearate by weight; and

(vii) 26.984% water by weight.

19. The method of claim 1 , wherein the composition comprises:

(i) 6% 5-methyl-1-phenyl-2(1H)-pyridone by weight;

(ii) 0.02% modified-diallyl disulfide oxide by weight;

(iii) 1% acrylamide/copolymer of sodium acryloylmethyl fumarate, isohexadecane polysorbate by weight;

(iv) 1% 2,2′,2″-nitrilotrietanol by weight;

(v) 2.5% 1,2-propanediol by weight; and

(vi) 89.479% water by weight.

20. The method of claim 1 , wherein the composition comprises:

(i) 8% 5-methyl-1-phenyl-2(1H)-pyridone by weight;

(ii) 0.016% modified-diallyl disulfide oxide by weight;

(iii) 1% Carbomer 940 by weight;

(iv) 1% 2,2′,2″-nitrilotrietanol by weight;

(v) 40% 1,2-propanediol by weight; and

(vi) 49.974% water by weight.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2021
From: MAGAÑA CASTRO, JOSÉ AGUSTÍN ROGELIO; ARMENDÁRIZ BORUNDA, JUAN SOCORRO
To: CELL THERAPY AND TECHNOLOGY, SA DE CV
Reel/Frame 055445/0624 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2020
From: CELL THERAPY TECHNOLOGY S.A. DE C.V.
To: EXCALIBUR PHARMACEUTICALS, INC.
Reel/Frame 053418/0628 →
Priority Claims (1)
MX MX/a/2017/010486 · Aug 15, 2017 · national
Continuity (1)
Related Publication 20200253944A1 · Aug 13, 2020
Cited By (2)
US 12,667,561 US 12,702,713